The table below shows NEKTAR THERAPEUTICS's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$208.51M
-$175.71M
-$192.61M
-$304.01M
-$412.66M
-$313.29M
Capital expenditure
$171.00K
$1.47M
$865.00K
$5.68M
$14.99M
$7.26M
Investing cash flow
-$1.20M
$142.57M
$139.56M
$365.83M
$202.78M
$496.21M
Dividends paid
-
-
-
-
-
NKTR operating cash flow (10-K history)
NEKTAR THERAPEUTICS reported operating cash flow of -$208.51M for fiscal year 2025. That is down 18.7% from -$175.71M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$117.02M (FY 2016) to -$208.51M. Figures come from the company's audited annual reports as filed with the SEC.
